Published in J Infect Dis on January 01, 2000
Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest (2005) 2.84
Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest (2008) 2.35
T cell immune reconstitution following lymphodepletion. Semin Immunol (2007) 2.35
Factors influencing T-cell turnover in HIV-1-seropositive patients. J Clin Invest (2000) 2.15
Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS (2004) 1.75
Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr (2008) 1.49
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol (2012) 1.39
Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. Virology (2004) 1.26
HIV-1 replication and pathogenesis in the human thymus. Curr HIV Res (2003) 0.99
Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database. PLoS One (2011) 0.96
Thymic volume is associated independently with the magnitude of short- and long-term repopulation of CD4+ T cells in HIV-infected adults after highly active antiretroviral therapy (HAART). Clin Exp Immunol (2004) 0.93
HIV RNA suppression and immune restoration: can we do better? Clin Dev Immunol (2012) 0.92
Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. J Infect Dis (2009) 0.90
Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy. HIV Clin Trials (2011) 0.89
Evidence that androgens modulate human thymic T cell output. J Investig Med (2011) 0.88
Changes in thymus volume in adult HIV-infected patients under HAART: correlation with the T-cell repopulation. Clin Exp Immunol (2002) 0.87
Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction. AIDS (2013) 0.85
Entrapment of recent thymic emigrants in lymphoid tissues from HIV-infected patients: association with HIV cellular viral load. AIDS (2002) 0.83
Molecular and cellular mechanisms of Mycobacterium avium-induced thymic atrophy. J Immunol (2012) 0.83
Cocaine reduces thymic endocrine function: another mechanism for accelerated HIV disease progression. AIDS Res Hum Retroviruses (2011) 0.83
Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174. AIDS Res Hum Retroviruses (2010) 0.82
Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery. J Transl Med (2015) 0.80
Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery. AIDS Res Hum Retroviruses (2014) 0.77
Activation of the hypothalamic-pituitary-adrenal (HPA) axis contributes to the immunosuppression of mice infected with Angiostrongylus cantonensis. J Neuroinflammation (2016) 0.75
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med (2001) 5.33
Determinants of HIV-1 shedding in the genital tract of women. Lancet (2001) 5.10
Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med (1999) 4.74
Infection of the SCID-hu mouse by HIV-1. Science (1988) 4.37
Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods (2001) 4.25
HIV induces thymus depletion in vivo. Nature (1993) 3.73
Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2001) 3.69
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis (1998) 3.69
Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med (2001) 3.69
Delta-F508 cystic fibrosis mutation is not linked to intussusception: implications for rotavirus vaccine. J Paediatr Child Health (2003) 3.59
Long-term human hematopoiesis in the SCID-hu mouse. J Exp Med (1990) 3.59
A potential role for interleukin-7 in T-cell homeostasis. Blood (2001) 3.56
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS (2001) 3.35
Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA (1999) 2.82
Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J Exp Med (1993) 2.81
Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature. Clin Infect Dis (2001) 2.80
Susceptibility of organisms in the Mycobacterium fortuitum complex to antituberculous and other antimicrobial agents. Antimicrob Agents Chemother (1977) 2.74
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis (2001) 2.63
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med (1997) 2.55
HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant (2007) 2.50
Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS (2001) 2.47
Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci U S A (2002) 2.46
Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol (1998) 2.38
Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med (1998) 2.27
A hospital-based influenza immunization program, 1977-78. Am J Public Health (1983) 2.23
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med (2001) 2.13
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med (2001) 2.08
Evaluation of TruCount absolute-count tubes for determining CD4 and CD8 cell numbers in human immunodeficiency virus-positive adults. Site Investigators and The NIAID DAIDS New Technologies Evaluation Group. Clin Diagn Lab Immunol (2000) 2.07
HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity (1995) 2.07
ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest (1995) 2.04
Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients. J Med Virol (1987) 2.02
Impaired cell-mediated immunity in patients with classic hemophilia. N Engl J Med (1983) 2.01
Immune restoration with antiretroviral therapies: implications for clinical management. JAMA (2000) 1.99
Fragile X syndrome without CCG amplification has an FMR1 deletion. Nat Genet (1992) 1.91
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1991) 1.89
Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse. J Virol (1994) 1.87
Differential gene activation by glucocorticoids and progestins through the hormone regulatory element of mouse mammary tumor virus. Cell (1988) 1.78
Mechanisms of HIV-associated lymphocyte apoptosis. Blood (2000) 1.75
Novel meiosis-specific isoform of mammalian SMC1. Mol Cell Biol (2001) 1.74
Isolation and immunologic characterization of a human. B-lymphocyte-specific, cell surface antigen. J Exp Med (1976) 1.74
CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood (2001) 1.74
CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo. J Virol (1998) 1.72
Multisite comparison of CD4 and CD8 T-lymphocyte counting by single- versus multiple-platform methodologies: evaluation of Beckman Coulter flow-count fluorospheres and the tetraONE system. The NIAID DAIDS New Technologies Evaluation Group. Clin Diagn Lab Immunol (2000) 1.71
Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication. Proc Natl Acad Sci U S A (1993) 1.70
Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol (2008) 1.70
Direct evidence for thymic function in adult humans. J Exp Med (1999) 1.70
Association of mammalian SMC1 and SMC3 proteins with meiotic chromosomes and synaptonemal complexes. J Cell Sci (2000) 1.69
Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS (1998) 1.69
Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA (1998) 1.68
Shipment impairs lymphocyte proliferative responses to microbial antigens. Clin Diagn Lab Immunol (2000) 1.67
Human T cells in the SCID-hu mouse are phenotypically normal and functionally competent. J Immunol (1991) 1.65
Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev (1997) 1.65
Characterization of a phenotypically distinct subpopulation of Leu-2+ cells that suppresses T cell proliferative responses. J Immunol (1983) 1.65
CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation. J Immunol (1998) 1.64
Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis (2012) 1.62
Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection (1990) 1.61
Measles virus infection of thymic epithelium in the SCID-hu mouse leads to thymocyte apoptosis. J Virol (1996) 1.61
Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to SCID-hu Thy/Liv mice. J Exp Med (1999) 1.61
Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice. J Clin Invest (1999) 1.56
Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med (2013) 1.56
Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. Antimicrob Agents Chemother (1996) 1.54
Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis (2000) 1.51
Acquired immunodeficiency syndrome with Pneumocystis carinii pneumonia and Mycobacterium avium-intracellulare infection in a previously healthy patient with classic hemophilia. Clinical, immunologic, and virologic findings. Ann Intern Med (1983) 1.51
Activity of gentamicin against mycobacteria in vitro and against Mycobacterium tuberculosis in mice. J Infect Dis (1971) 1.51
Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother (1996) 1.51
Sonographic findings in perforation of the gallbladder. AJR Am J Roentgenol (1982) 1.51
NIH conference. Chronic fatigue syndrome research. Definition and medical outcome assessment. Ann Intern Med (1992) 1.50
Invasive infection with Saccharomyces cerevisiae: report of three cases and review. Rev Infect Dis (1990) 1.49
Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med (1995) 1.48
Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995--1999. Clin Infect Dis (2000) 1.47
Two types of Ia-positive T cells. Synthesis and exchange of Ia antigens. J Exp Med (1980) 1.47
Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. Clin Immunol (1999) 1.47
Herpes simplex virus hepatitis: expanding the spectrum of disease. Transpl Infect Dis (2006) 1.46
A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. AIDS (2001) 1.45
Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS (2000) 1.41
Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. J Virol Methods (1998) 1.41
Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. J Virol (1998) 1.41
Endoscopic treatment of a choledochocele in a 2-year-old child. Surg Endosc (1996) 1.40
Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. AIDS (1999) 1.40
LAT is required for tyrosine phosphorylation of phospholipase cgamma2 and platelet activation by the collagen receptor GPVI. Mol Cell Biol (1999) 1.38